Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 406Carcinoma, Non-Small-Cell Lung 147Urinary Bladder Neoplasms 87Breast Neoplasms 84Cholangiocarcinoma 82Lung Neoplasms 78Neoplasm Metastasis 67Neoplasms 64Biliary Tract Neoplasms 58Nasopharyngeal Carcinoma 53Ovarian Neoplasms 46Sarcoma 43Recurrence 39Gallbladder Neoplasms 39Hodgkin Disease 34Lymphoma, Large B-Cell, Diffuse 33Lymphoma 32Carcinoma, Transitional Cell 29Bile Duct Neoplasms 24Adenocarcinoma 23Fallopian Tube Neoplasms 19Carcinoma, Hepatocellular 19Adenocarcinoma of Lung 18Triple Negative Breast Neoplasms 17Lymphoma, Non-Hodgkin 17Liver Neoplasms 17Nasopharyngeal Neoplasms 16Lymphoma, Extranodal NK-T-Cell 16Carcinoma 16Non-Muscle Invasive Bladder Neoplasms 15

Interventions

Electroporation 2monomethyl auristatin E 1Oxaliplatin 1Gemcitabine 1Cryosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Unresectable Pancreatic Cancer × Gemcitabine × Clear all
NCT02035072 2017-07-21

Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed
40 enrolled
Gastrointestinal

Unresectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡